Amalgamated Financial’s Anika Therapeutics ANIK Stock Holding History

Amalgamated Financial’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$161K	Buy	+6,428	New	+$196K	﹤0.01%	1981

Other funds holding ANIK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Trigran Investments Northbrook, Illinois $418M AUM 3.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FWIA

Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return

Amalgamated Financial's ANIK Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Anika Therapeutics (ANIK) in Q1 2022: 6,428 shares worth $161K. The stake represents ﹤0.01% of the portfolio and ranks #1981 among its holdings.

119 funds tracked by Wall St. Rank hold ANIK as of Q1 2022.

Amalgamated Financial held 6,428 shares of Anika Therapeutics worth $161K as of Q1 2022.
Anika Therapeutics was a new Amalgamated Financial position in Q1 2022.
Anika Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #1981 holding.
119 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.